Leadership Change Recent leadership appointment of Stewart Strong as President and CEO in July 2025 signals potential strategic shifts and renewed focus on growth, partnerships, and expansion opportunities in neurovascular interventions.

Growth Signals Revenue range of 10-25 million with total funding of 69 million indicates a scaling company with financial runway to pursue new product launches, clinical collaborations, and regional market expansion.

Product Focus flagship Hippo aspiration system and 072 Hippo line emphasize neurovascular access innovation, presenting opportunities to upsell corresponding delivery tools, disposables, training, and integrated workflow solutions to hospitals and stroke centers.

Strategic Partnerships Active legal and competitive dynamics with Route 92 Medical over delivery catheter technologies highlight a landscape where Q’Apel can pursue strategic partnerships, licensing discussions, or cross-portfolio collaborations to strengthen market position.

Operational Scale Smaller company footprint with 51-200 employees while leveraging broad tech stack (SOLIDWORKS, NetSuite, Salesforce, cloud services) suggests a readiness to adopt scalable sales engines, value-based procurement approaches, and accelerated onboarding for new customers and clinical sites.